LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) and Daiichi Sankyo's (4568.T) Enhertu has been recommended for approval in the European Union by CHMP as a monotherapy for the adjuvant treatment of adult patients with resected HER2-positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted treatment. The Committee for Medicinal Products for Human Use of the European Medicines Agency based its positive opinion on results from the DESTINY-Breast05 Phase III trial.
Enhertu is approved in the US and other countries for the adjuvant treatment of patients with HER2-positive breast cancer who have residual invasive disease following neoadjuvant treatment based on DESTINY-Breast05. Enhertu was discovered by Daiichi Sankyo and is jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
At last close on LSE, AstraZeneca shares were trading at 12,500.00 pence.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
